The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally. Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.
CRISPR Genomic Cure Market Size to Reach $14 80 Billion, Globally, by 2030 at 34 7% CAGR: Coherent Market Insights (CMI)
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Crispr Genomic Cure Market to Reach $14 80 Billion, Globally, by 2030 at 34 7% CAGR: CRISPR Therapeutics AG, Caribou Biosciences, GenScript Biotech Corporation |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
The CRISPR Genomic Cure Market Size Is Expected To Reach US$ 14 80 Billion By 2030 Says Coherent Market Insights
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.